MedTrace Logo

Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health

NCT05309226 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2025-04-16

No results posted yet for this study

Summary

With perinatal cannabis use rising in Canada, robust data on short-term and long-term effects on newborns are urgently needed. However, past barriers to obtain robust data included limited sample sizes, low self-reporting and no account of postpartum exposures. Therefore, this study will be conducted as a feasibility pilot study to tease out limitations that were present in previous studies. This study will help us dictate how to conduct a larger prospective cohort study to answer any knowledge gaps currently in the field of perinatal cannabis use.

Conditions

  • Cannabis Use
  • Marijuana Use

Interventions

OTHER

Cannabis use in pregnancy or cannabis exposure in utero

Cannabis-related product use in pregnancy. Cannabis-related products will include all forms (e.g., dry flower, edibles, extracts, etc.) and formats of consumption (e.g., joint, bong, capsule, tincture, etc.).

Sponsors & Collaborators

  • Kingston Health Sciences Centre

    collaborator OTHER

  • Children's Hospital of Eastern Ontario Research Institute

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Mark Walker, MD, MSc, MHM · Ottawa Hospital Research Institute

  • Daniel Corsi, PhD · Ottawa Hospital Research Institute

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-10
Primary Completion
2025-01-07
Completion
2025-02-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05309226 on ClinicalTrials.gov